Literature DB >> 12941139

Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation.

Marc Dauer1, Katrin Pohl, Bianca Obermaier, Tobias Meskendahl, Julian Röbe, Max Schnurr, Stefan Endres, Andreas Eigler.   

Abstract

Dendritic cells (DC) can be derived from monocytes in vitro by culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). It is unknown whether this regimen reflects DC differentiation from blood precursors under physiological conditions. Induction of DC development from monocytes by interferon-alpha (IFN-alpha) may occur in vivo during infection or inflammation and thus may represent a more physiological approach to DC differentiation in vitro. Here, we show that incubation of GM-CSF-cultured monocytes with IFN-alpha does not induce DC differentiation: cells maintain their original phenotype and cytokine secretion pattern. Even after stimulation with pro-inflammatory or T-cell-derived activation signals, IFN-alpha-treated monocytes do not develop DC characteristics. Addition of IL-4 during stimulation of IFN-alpha-treated monocytes results in the rapid development of DC-like cells expressing co-stimulatory molecules, CD83 and chemokine receptor CCR7, indicating that some degree of developmental plasticity is preserved. However, DC pre-activated with IFN-alpha are less effective in inducing allogeneic or antigen-specific autologous T-cell proliferation, produce less IL-12 and express lower levels of CCR7 compared to DC generated by culture with GM-CSF and IL-4. Incubating GM-CSF-cultured monocytes simultaneously with IFN-alpha and IL-4 does not affect phenotypic maturation of DC, but reduces IL-12 production upon pro-inflammatory activation. We conclude that: (1) IFN-alpha fails to induce DC differentiation and thus cannot replace IL-4 in generating DC from monocytes in vitro; and (2) the presence of IFN-alpha prior to or during differentiation of DC from monocyte precursors alters their response to maturation stimuli and may affect their capacity to stimulate T helper type 1 immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941139      PMCID: PMC1783028          DOI: 10.1046/j.1365-2567.2003.01702.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  The disabled dendritic cell.

Authors:  M Thurnher; C Zelle-Rieser; R Ramoner; G Bartsch; L Höltl
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

Review 2.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

3.  Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity.

Authors:  A A Byrnes; X Ma; P Cuomo; K Park; L Wahl; S F Wolf; H Zhou; G Trinchieri; C L Karp
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

4.  Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.

Authors:  M Schnurr; P Galambos; C Scholz; F Then; M Dauer; S Endres; A Eigler
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

5.  Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization.

Authors:  M Cella; F Facchetti; A Lanzavecchia; M Colonna
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

6.  Interferon-beta induces the development of type 2 dendritic cells.

Authors:  Y M Huang; Y Hussien; D Yarilin; B G Xiao; Y J Liu; H Link
Journal:  Cytokine       Date:  2001-03-07       Impact factor: 3.861

7.  Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells.

Authors:  M Lehner; T Felzmann; K Clodi; W Holter
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

8.  Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.

Authors:  S Parlato; S M Santini; C Lapenta; T Di Pucchio; M Logozzi; M Spada; A M Giammarioli; W Malorni; S Fais; F Belardelli
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

9.  Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors.

Authors:  B L McRae; T Nagai; R T Semnani; J M van Seventer; G A van Seventer
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

10.  A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use.

Authors:  B Feuerstein; T G Berger; C Maczek; C Röder; D Schreiner; U Hirsch; I Haendle; W Leisgang; A Glaser; O Kuss; T L Diepgen; G Schuler; B Schuler-Thurner
Journal:  J Immunol Methods       Date:  2000-11-01       Impact factor: 2.303

View more
  20 in total

1.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

2.  Usp18 promotes conventional CD11b+ dendritic cell development.

Authors:  Xiu-Li Cong; Miao-Chia Lo; Brian A Reuter; Ming Yan; Jun-Bao Fan; Dong-Er Zhang
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

3.  Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.

Authors:  Mark J Bluth; Lisa C Zaba; Dariush Moussai; Mayte Suárez-Fariñas; Helen Kaporis; Linda Fan; Katherine C Pierson; Traci R White; Alexander Pitts-Kiefer; Judilyn Fuentes-Duculan; Emma Guttman-Yassky; James G Krueger; Michelle A Lowes; John A Carucci
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

4.  Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation.

Authors:  Jui-Hung Yen; Doina Ganea
Journal:  Blood       Date:  2009-06-16       Impact factor: 22.113

5.  Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection.

Authors:  Shashi A Gujar; Adam K Jenkins; Clifford S Guy; Jinguo Wang; Tomasz I Michalak
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

6.  Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC).

Authors:  Jessica L Reynolds; Supriya D Mahajan; Donald E Sykes; Stanley A Schwartz; Madhavan P N Nair
Journal:  Biochim Biophys Acta       Date:  2007-02-13

7.  Expression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1 alpha DCs induced in vivo by IFN-alpha in patients with chronic hepatitis B.

Authors:  Yong-Sheng Yu; Zheng-Hao Tang; Jing-Chao Han; Min Xi; Jie Feng; Guo-Qing Zang
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

8.  Methamphetamine modulates DC-SIGN expression by mature dendritic cells.

Authors:  Madhavan P N Nair; Supriya Mahajan; Don Sykes; Meghana V Bapardekar; Jessica L Reynolds
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-23       Impact factor: 4.147

9.  Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis.

Authors:  Shashi A Gujar; Patricia M Mulrooney-Cousins; Tomasz I Michalak
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

10.  Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection.

Authors:  Shashi A Gujar; Tomasz I Michalak
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.